Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of SIBP-V03-I Influenza Vaccine
NCT06342349Phase 1Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of quadrivalent influenza virus split vaccine (MDCK cells) in influenza (3 arms), sponsored by Shanghai Institute of Biological Products. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 1 more. Started Mar 2024; status: completed.
02
Drugs
quadrivalent influenza virus split vaccine (MDCK cells)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06342349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342349.